On The Respiratory Horizon: A Wave Of Biologics For Asthma
Executive Summary
Several antibody drugs are in late-stage development to treat severe asthma and could reach the market in the next two years. But competition for niche subsets of patients will be fierce, and tailoring the right medications to the right patients to justify the higher cost of treatment will require advances in biomarker development.
You may also be interested in...
AstraZeneca Hopes To Differentiate Benralizumab On Efficacy, Dosing Convenience
Biologic for severe asthma meets primary endpoint in two pivotal studies, but greater detail will be needed to differentiate the drug from already-approved Nucala and Cinqair.
Roche Reviewing Next Steps For Lebrikizumab After Mixed Phase III Data
One of two identical Phase III trials testing the IL-13 blocker in severe asthma patients met its primary endpoint, while the other failed.
GSK’s Mepolizumab Panel Review May Hinge On Eosinophil Utility In Patient Selection
With a high regulatory bar for safety and efficacy for new asthma drugs and a skeptical payer base, the significance of and effect on eosinophil counts will be a crucial consideration for the severe asthma candidate.